Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALDA Enters National Phase with New Patent Application
Vancouver, BC - ALDA Pharmaceuticals Corp. (APH:TSX-V, APCSF:OTCQB) (the “Company” or “ALDA”) has filed its patent application, “Antiseptic Compositions for the Treatment of Infections”, with the US Patent and Trademark Office (Serial #12/933,358). The application, first submitted to the Canadian Intellectual Property office for review in March, 2008 under the Patent Cooperation Treaty, seeks protection for the composition and preparation of T36® formulations that also contain steroids, anesthetics or analgesics for use on topical infections and, in particular, inflamed infections. Typically, infections with associated inflammation are treated with separate antiseptic and anti-inflammatory preparations. The new T36® formulations combine these properties into a single treatment, making the prescription process easier for the physician and the application easier for the patient. Submissions to the European and Canadian patent offices are also planned. This patent is the third in a series of patents providing protection for the T36® technology that have been issued or are pending.
The first patent, providing protection for the composition and production methods for ALDA's T36® formulation until August 20, 2022, is:
· issued in Australia (#2002322916), the US (#7,338,927) and China (#ZL02829642.7),
· allowed and pending in Canada (Patent Application #2,495,938) and
· pending in the EU (Patent Application #02754054.1-2113).
The second patent, providing protection for the use of T36® as a component of a personal lubricant, in a method of preventing or reducing the transmission of a sexually transmitted diseases including Herpes, Chlamydia and HIV and for use in sanitizers and cleansers in creams, ointments and wipes until August 20, 2022, is
· issued in Australia (#2007237333) and the US (#7,560,422),
· allowed and is pending in Canada (Patent Application #2,495,938) and
· pending in China (Chinese Divisional Patent Application #200710142798.3) and the EU (Patent Application #02754054.1-2113).
According to Dr. Terrance Owen, President & CEO, “Intellectual property protection is one of the key assets of emerging pharmaceutical companies. We are committed to building the Company’s patent portfolio so that we have the protection required in the main international markets that we are targeting with the therapeutic products derived from the T36® technology”.
ALDA Enters Into Joint Venture with Seavan
Vancouver, BC - ALDA Pharmaceuticals Corp. (APH:TSX-V) (the “Company” or “ALDA”) announces that a joint venture agreement has been established with Seavan Health & Beauty Partnership (“Seavan”). Under the terms of the agreement, Seavan will manufacture ALDA’s products and ALDA’s personnel will undertake the marketing and sales of Seavan’s products and services in addition to those of ALDA. The acquisition of substantially all of the assets and undertakings of Seavan by ALDA is still in progress.
Dr. Terrance Owen, President & CEO states, “During our discussions with Seavan, it became clear that it would be beneficial for us to work together now because the two companies are very complimentary and can benefit from each other’s strengths. This joint venture will allow us to combine our resources, fine-tune our delivery of both ALDA’s and Seavan’s products and services and grow both businesses as we work on the acquisition. The ultimate goals are for ALDA to manufacture as well as distribute T36® products, acquire expertise in R&D, quality assurance and regulatory matters and re-focus on the therapeutic applications of the T36® technology”.
About Seavan Health & Beauty Partnership (www.seavanlabs.com)
Seavan, located in Vancouver, manufactures pharmaceutical, nutritional and personal care products under licenses from Health Canada and the FDA. Examples of products manufactured at Seavan include glucosamine and magnesium supplements, sun screens, topical delivery systems, pain relievers, body washes, hair care products and ALDA’s T36® products.
Im enjoying the virtual beers going around...However I recommend everyone stays away from the grape cool aid Drumsticks drinking. ;)
Id say its a great opportunity for you to complain and feel terrible about yourself.
Haha. Odd jobs. Im laughing picturing TO painting my fence!
Shes got a heart beat ladies and gentleman! Everyone's doing a great job being patient here. I still believe!
Yes Drumstick, misery loves company and your not alone.
I attended ski jump qualifying, and mens skeleton finals at the 2010 Olympics, both events being in Whistler. T36 was at each event and in every port-o-potty.
Enjoy your day
:)
No apology needed. We are entitled to our opinions. :)
I know SP is not what we were hoping it would be post 2010 Olympics...Drumstick, considering whats going on in Europe and how its effecting the rest of the world, I think "market conditions" do have influence on what we are seeing.
To me it really seems that TO is lining up his chess pieces very effectively. I am still convinced that with some patience we will eventually see the profitability we are waiting for.
LETTER TO THE SHAREHOLDERS OF ALDA Pharmaceuticals Corp.
In public companies, the Management Discussion and Analysis (“MD&A”) that is prepared every quarter provides an overview of a company from its beginning up to the date of the document. The intention is to provide a source of information that fully describes the company to anyone, including a person who has never seen any information on the company before. Due to the level of activity at ALDA Pharmaceuticals Corp. and a long history of events, the MD&A is now almost 50 pages long. The intent of this letter is to summarize the highlights of the quarter ended March 31, 2010.
2010 Olympic and Paralympic Winter Games
During the last quarter, the Company was kept very busy servicing the 2010 Olympic and Paralympic Winter Games. Activities included product preparation and delivery, servicing dispensing equipment for T36® Antiseptic Hand Sanitizer and, after the Games, removing equipment and managing inventory. ALDA products were seen throughout the Games and received a very positive response. The focus now is to capitalize on the credibility and exposure provided by the Games. We retain our core customers and are committed to servicing the new ones that were established as a result of the Official Supplier status. We are also pursuing the opportunities that occurred from the high demand for sanitation products observed during the last three months of 2009. April and May were very busy with trade shows and visiting customers with outlets and representation across Canada. We are in the process of visiting as many of these outlets as we can and, again, we are receiving a very positive response to ALDA’s products. We are finding that we can differentiate our products from the others due to the safety advantage and effectiveness of the T36® products. Our association with the Olympics has provided an important way for us to introduce the Company and its products to prospective new customers. Now that the excitement and bustle of the Olympics is over, the job now is expand across Canada and into new territories.
2010 TSX Venture 50
A surprise phone call from the TSX Venture Exchange brought good news. We were advised that ALDA had been selected as one of the 2010 TSX Venture 50. The Exchange describes this group of companies as a ranking of strong performers listed on TSX Venture Exchange comprised of 10 emerging companies in five industry sectors that have been identified as leaders in Canada’s public venture capital market. The selection of the 2010 TSX Venture 50 was based on four equally weighted criteria that include return on investment, trading, analyst coverage and market capitalization growth in Cleantech, Diversified Industries, Mining, Oil & Gas and Technology and Life Sciences sectors. ALDA was Number 3 in Technology and Life Sciences. When we attended the reception in Toronto on April 7, we were able to tell people that we may have been #3 in our category but we were Number 1 on the street because ALDA was the top trader and top gainer. We traded over 14.5 Million shares that day, a new record for ALDA, and the share price increased by 115%. By April 15, over 28 Million shares had traded with 4 houses accounting for over 60% of the trades.
NDC Labeller Code
The triggering event for this rather active trading day was the announcement that ALDA had received its “NDC” (National Drug Code) Labeler Code from the FDA. If products are described in the “1994 Tentative Final Monograph for OTC Healthcare Antiseptic Drug Products” they can be sold without efficacy or toxicology studies due to the known properties of standard ingredients. An example is 60 to 95% ethanol-based hand sanitizers. The labelling requirements for the US are different from Canada and new labels for the first products are in progress.
Australian Patent
Another event that occurred in the last quarter was the issuance of Australian Patent Number 2007237333. This new patent is a continuation of Australian Patent Number 2002322916 that was granted on January 10, 2008. Further protection is now provided for ALDA's T36® formulation, including the use of T36® to prevent or reduce the transmission of sexually transmitted infections and as a sanitizer or cleanser in the form of creams, ointments and wipes. Since Commonwealth countries, like Australia, represent potential markets for ALDA, having intellectual property protection in place is an important step.
Therapeutic products
Work continues on the registration of T36® for therapeutic applications. An “IND” (Investigational New Drug”) application was submitted to the FDA early in the new year. The FDA responded with information on what test results and other information that needs to be provided before human clinical trials may begin. The recent appointment of Dr. Brian Conway to the position of Medical Director will be of great assistance to the Company as we move forward with our clinical plans.
Private Placement
The private placement that was planned in April has been amended twice due to the changing market conditions. Initially, the placement was oversubscribed and the number of Units was increased from 2.5 Million to over 3 Million. Then, the turmoil in Europe took its toll on the market so the price was dropped from $0.20 to $0.15 on May 28. We now have until the end of June to close the placement.
Future plans
The plan for the short term is to focus on sales, introduce new products, pursue product registrations in other countries and prepare the documentation required by the FDA. In the medium term, the goals are to establish agents and sales in other countries and complete the testing required by the FDA to allow human trials. In the long term, the Company will focus on completion of the clinical trials for the therapeutic products. We expect this to keep us quite busy for some time and to make the MD&A even longer.
“Terrance Owen”
Terrance G. Owen, Ph.D., M.B.A.
President & CEO
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Ya I dont think the hand sanitizer is much of a cash cow at the moment. Its off season for one thing. I do believe that the investment of being an Olympic supplier and the FDA approval are going to help TO get the funding we need to develop further therapeutic products for the American, and global, markets.
SO yes, I too do not expect great numbers this quarter, but remain confident with the long term prospects.
Im convinced that Alda is headed in a very good direction.
I just doubled up.
Exciting times.....
Im glad to hear you weathered the storm Drumstick.
Seems very likely we you will see the SP you (and everyone else here) have been looking for soon enough.
:)
Drumstick? Oh DRUMSTICK?
You still with us?.....
I think we lost him.
Way to go Alda!
And way to go fellow investors that remained positive. We invested on the basis of strong fundamentals, and we knew that hadn't changed.
Looking forward to what lies in the future.
THIS IS HUGE!
WOW!
I think all this positivity may have scared you-know-who off....
I just averaged down....
I can find the Journal de Montreal website, but not the cover from March 18...
Can you provide a link there Drumstick?
I couldnt agree more, Surfin. I figure the brightest crayons in the box are lookin to average down right about now.
NEWS RELEASE
APH:TSX-V, APCSF:OTCBB March 2, 2010
ALDA receives Australian Patent for T36® Disinfectant
Vancouver, BC - ALDA Pharmaceuticals Corp. (APH:TSX-V, APCSF:OTCBB, "ALDA") is pleased to
announce that Australian Patent Number 2007237333 has been issued by the Australian Patent Office.
This new patent is a divisional of Australian Patent Number 2002322916 that was issued on January 10,
2008 and provides further protection for ALDA's T36® formulation until August 20, 2022. The
divisional patent includes claims to additional aspects of the T36® formulation, including the use of T36®
as a component of a personal lubricant, in a method of preventing or reducing the transmission of
sexually transmitted diseases including Herpes, Chlamydia and HIV and as a sanitizer or cleanser in the
form of creams, ointments and wipes. The divisional patent also includes claims to methods of
producing T36®.
Dr. Terrance Owen, President & CEO, states, "This new Australian patent is another important asset in
our intellectual property portfolio because it provides additional protection for T36®. It also ties in well
with our strategy of registering T36® for therapeutic applications and complements the more recent PCT
application which covers a number of additional therapeu tic applications.”
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36®
technology. The company trades on the TSX Venture Exchange under the symbol APH and on the
OTCBB under the symbol APCSF. The Company is the Official Supplier of the Vancouver 2010
Olympic Winter Games, Vancouver 2010 Paralympic Winter Games, the Canadian Olympic Committee,
the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer,
disinfectant and disinfectant cleaning products. The Company has also been selected as one of the TSX
Venture 50 companies in the Technology and Life Sciences sector for 2010.
Terrance G. Owen, Ph.D., MBA
President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com
Sales Management 604-521-8300
Diane Mann , Account Executive Extension 4 diane_mann@aldacorp.com
Tracy Haubrich, Account Manager Extension 7 tracy_haubrich@aldacorp.com
Steve Cozine, Account Manager Extension 6 steve_cozine@aldacorp.com
Retail Sales
London Drugs, Shoppers Drug Mart, T&T Supermarket, IGA Marketplace, Pharmasave
I was lucky enough to score Olympic tickets for 2 events in Whistler this past friday. Overall I was pleased actually how it was not a corporate ad fest. I was not bombarded with RBC and Coke ads(major sponsors paying a hell of a lot more then little Alda).
However, to my excitement, I did observe a T36 presence. Every security point I went through had T36 dispensers at each gate, with the logo in plain view. Plus every one of the 1000s of port-o-potties had a T36 dispenser with the logo on it.
Also, I actually overheard someone talking about how "it itsnt Purell?!..Whos this T36 stuff?"
Hey its all good Safeguy. Im glad to see some more coverage as well, and to see you excited!
Actually, Terry has already carried it last month. And there is a ban on any corporate logo flashing when carrying the torch.
I believe other employees and relations of Alda will have a chance to carry the flame....
Good call SurfinNj. Heres the letter to shareholders as predicted! There are definitely some interesting details in here and some exciting possibilities.
http://www.aldacorp.com/download/newsreleases/SH_aph_Letter_aph_18Jan10.pdf
seems SOMEONE out there is an optimist ;)
Yeah they're totally still in the game. They would not be allowed to have the logo on their ads or their website if they had dropped out.
Vanoc would not allow that.
In regards to the 3-15 million....Wouldn't this sort of fee be payable over time, and not necessarily upfront as a lump sum?
It did have the Olympic logo on it. Other then that, the graphics were the two kids from the website homepage. Unfortunately it did not have any image of the product on it, but it did have the T36 logo.
There are large T36 advertisements at Skytrain stations all over Vancouver now.
On the upside, i would think that the quarterly report reflecting the end of 2009 will show far more sales then ever before. No?
Id have to agree.
Cheers Woodstock135
This article is on the front page of the New Westminster local paper, "The Record".
http://www2.canada.com/newwestrecord/story.html?id=ee938870-7350-45d3-b3a8-fd5140be06e9
ALDA Official Supplier Richmond Olympic Oval
http://www.aldacorp.com/download/newsreleases/Richmond_aph_Oval_aph_news_aph_FINAL.pdf
Here is the Business in Vancouver article I scanned for those of you who don't have a subscription.
http://i230.photobucket.com/albums/ee184/jessewinchester/businessvancouver1.jpg
http://i230.photobucket.com/albums/ee184/jessewinchester/businessvancouver2.jpg
Cheers
-Winchester
A friend told me yesterday that T36 is all over the Vancouver Airport now.
Also Terry Owen is on the front page of Business in Vancouver publishing this week.
http://www.biv.com/thisweek.asp
Yes this is what weve all been waiting for. The exposure of T36 at the Olympics combined with its availability on store shelves is sure to increase profits and therefor our stock value!
I cant help but wonder if London Drugs is just the beginning!
YAY!